TOS-358 breast cancer study is recruiting: what the phase 1 registry entry shows — LiveFuture News
Open on LiveFuture.ai →

TOS-358 breast cancer study is recruiting: what the phase 1 registry entry shows

A ClinicalTrials.gov registry observation shows Totus Medicines’ phase 1 study of TOS-358 in women with HR+ HER2- breast cancer is recruiting, with safety and tolerability as the main focus.

A new ClinicalTrials.gov registry observation shows that a phase 1 study of TOS-358 in women with HR+ HER2- breast cancer is recruiting. For readers following treatment research, the immediate takeaway is simple: the study is open, but its outcomes are not posted yet, so the public can see the design, not the answer.

The registry lists Totus Medicines as sponsor and gives the study as non-randomized. It also gives a current status of RECRUITING and an estimated primary completion date of 2027-12, which means this is still an early-stage safety and tolerability study rather than a finished comparison of results.

What the study is testing

The study title says it is evaluating the safety and tolerability of TOS-358 in women with HR+ HER2- breast cancer. That is a careful first step in drug development: before a medicine is judged on benefit, researchers first watch closely for harm and how people handle the treatment.

Three arm groups are listed: TOS-358 + fulvestrant, TOS-358 + fulvestrant + CDK4/6i, and TOS-358. Fulvestrant is a drug, and CDK4/6i refers to a CDK4/6 inhibitor, a type of cancer medicine used in breast cancer treatment. The registry names palbociclib and ribociclib under that combination arm.

What success will be measured by

The primary outcomes focus on safety. The study will determine the rate of dose-limiting toxicities in the first 21 days of treatment, then track the incidence and severity of adverse events and specific laboratory abnormalities from the start of treatment to 30 days after the last dose.

That means the registry is asking a practical question about whether the treatment can be given safely enough to justify later testing. It does not yet say whether TOS-358 works better than another option, and the record itself says study outcomes require posted results.

Why this trial fits the wider cancer research picture

This registry observation also sits within the active Cancer Breakthroughs special event, alongside other cancer studies that are recruiting or not yet recruiting. The shared thread is early-stage development across different cancers and treatment strategies, from drug combinations to broader treatment comparisons.

A useful way to read this entry is as a sign of movement, not conclusion. The trial is live, the design is defined, and the next public milestone in the record is still ahead. For anyone tracking breast cancer research, that is the main news: the study is underway, but the answer is still pending in future results.